Constrained Serotonin Agonists Reducing Cardiotoxicity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current psychedelic-based therapies for psychological disorders, such as depression and PTSD, are limited by their hallucinogenic effects and cardiotoxicity, necessitating the development of non-hallucinogenic and non-cardiotoxic tryptamine-like analogs or mimetics for safe, at-home administration.
Innovation Solution
Development of compounds of Formula I, which are serotonin receptor agonists that can be administered in a therapeutically effective amount to treat psychological disorders, inflammation, and pain, without the need for medical oversight, by forming a 3- to 7-membered heterocyclic ring structure with specific substituents to minimize cardiotoxicity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If psychedelic drugs like psilocybin and LSD are used to treat psychological disorders, then therapeutic effectiveness is improved, but hallucinogenic effects and cardiotoxicity worsen
Solution Approach 1:
The patent applies parameter changes by modifying the chemical structure of tryptamine compounds through specific substitutions at positions 3 and 4 of the indole ring, and by introducing conformational constraints. These structural parameter changes result in compounds that maintain 5-HT2A receptor agonist activity (therapeutic effectiveness) while eliminating hallucinogenic effects and cardiotoxicity associated with traditional psychedelics
2Reliability
If traditional psychedelic drugs are administered, then neuroplasticity and mood improvement are achieved, but medical oversight and clinical setting requirements worsen ease of operation
Solution Approach 1:
The patent employs parameter changes by designing compounds with specific structural features (substitutions at positions 3 and 4, conformational constraints) that fundamentally alter the drug's safety profile. These changes enable the compound to induce neuroplasticity and improve mood while being safe enough for self-administration at home without medical oversight, thus resolving the contradiction between therapeutic reliability and ease of operation
3Object-affected harmful factors
If tryptamine analogs are developed to reduce side effects, then safety is improved, but structural complexity increases
Solution Approach 1:
The patent applies parameter changes through systematic modification of the tryptamine core structure, specifically at positions 3 and 4 of the indole ring, and by introducing conformational constraints. These targeted structural changes reduce cardiotoxicity while maintaining therapeutic activity, demonstrating that controlled parameter changes can improve safety without excessive complexity increase
Solution Approach 2:
The patent employs segmentation by dividing the molecular structure into functional regions: the core indole structure that maintains 5-HT2A activity, the substituted positions 3 and 4 that reduce cardiotoxicity, and conformational constraints that eliminate hallucinogenic effects. This segmentation allows independent optimization of each region to achieve the desired balance between safety and efficacy
Data Source
AI summary
Serotonin receptor agonists, including conformationally constrained serotonin receptor agonists, and methods of making and using the same are disclosed herein.